| 2011 update of the drug resistance mutations in HIV-1 VA Johnson, V Calvez, HF Günthard, R Paredes, D Pillay, R Shafer, ... Topics in antiviral medicine 19 (4), 156, 2011 | 1175 | 2011 |
| Remdesivir for the treatment of Covid-19—preliminary report JH Beigel, KM Tomashek, LE Dodd, AK Mehta, BS Zingman, AC Kalil, ... New England Journal of Medicine, 2020 | 817 | 2020 |
| 2015 update of the drug resistance mutations in HIV-1 AM Wensing, V Calvez, HF Günthard, VA Johnson, R Paredes, D Pillay, ... Top Antivir Med 23 (4), 132-41, 2015 | 676 | 2015 |
| Special contribution 2014 Update of the drug resistance mutations in HIV-1 AM Wensing, V Calvez, HF Günthard, VA Johnson, R Paredes, D Pillay, ... Topics in antiviral medicine 22 (3), 642, 2014 | 676* | 2014 |
| Special contribution 2014 Update of the drug resistance mutations in HIV-1 AM Wensing, V Calvez, HF Günthard, VA Johnson, R Paredes, D Pillay, ... Topics in antiviral medicine 22 (3), 642, 2014 | 676* | 2014 |
| HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects MJ Buzón, M Massanella, JM Llibre, A Esteve, V Dahl, MC Puertas, ... Nature medicine 16 (4), 460-465, 2010 | 578 | 2010 |
| Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a … L Wittkop, HF Günthard, F De Wolf, D Dunn, A Cozzi-Lepri, A De Luca, ... The Lancet infectious diseases 11 (5), 363-371, 2011 | 380 | 2011 |
| Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis JZ Li, R Paredes, HJ Ribaudo, ES Svarovskaia, KJ Metzner, MJ Kozal, ... Jama 305 (13), 1327-1335, 2011 | 349 | 2011 |
| Prospective randomized two-arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy. A Tuldrà, CR Fumaz, MJ Ferrer, R Bayés, A Arnó, M Balagué, A Bonjoch, ... Journal of acquired immune deficiency syndromes (1999) 25 (3), 221-228, 2000 | 323 | 2000 |
| Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population AJ Rodger, R Lodwick, M Schechter, S Deeks, J Amin, R Gilson, ... Aids 27 (6), 973-979, 2013 | 320 | 2013 |
| Update of the drug resistance mutations in HIV-1: March 2013 VA Johnson, V Calvez, HF Günthard, R Paredes, D Pillay, RW Shafer, ... Topics in antiviral medicine 21 (1), 6, 2013 | 302 | 2013 |
| Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study R Paredes, A Mocroft, O Kirk, A Lazzarin, SE Barton, J Van Lunzen, ... Archives of internal medicine 160 (8), 1123-1132, 2000 | 284 | 2000 |
| Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo AMN Tsibris, B Korber, R Arnaout, C Russ, CC Lo, T Leitner, B Gaschen, ... PloS one 4 (5), e5683, 2009 | 238 | 2009 |
| Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression L Ruiz, J Martinez-Picado, J Romeu, R Paredes, MK Zayat, S Marfil, ... Aids 14 (4), 397-403, 2000 | 233 | 2000 |
| Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure R Paredes, CM Lalama, HJ Ribaudo, BR Schackman, C Shikuma, ... The Journal of infectious diseases 201 (5), 662-671, 2010 | 216 | 2010 |
| Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and … E Negredo, L Cruz, R Paredes, L Ruiz, CR Fumaz, A Bonjoch, S Gel, ... Clinical infectious diseases 34 (4), 504-510, 2002 | 212 | 2002 |
| Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy: 1-year prospective follow-up of a … L Ruiz, E Negredo, P Domingo, R Paredes, E Francia, M Balagué, S Gel, ... Journal of acquired immune deficiency syndromes (1999) 27 (3), 229-236, 2001 | 204 | 2001 |
| Gut microbiota linked to sexual preference and HIV infection M Noguera-Julian, M Rocafort, Y Guillén, J Rivera, M Casadellà, P Nowak, ... EBioMedicine 5, 135-146, 2016 | 189 | 2016 |
| Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens CR Fumaz, A Tuldra, MJ Ferrer, R Paredes, A Bonjoch, T Jou, E Negredo, ... JAIDS-HAGERSTOWN MD- 29 (3), 244-253, 2002 | 178 | 2002 |
| HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection L Ruiz, G Carcelain, J Martínez-Picado, S Frost, S Marfil, R Paredes, ... Aids 15 (9), F19-F27, 2001 | 177 | 2001 |
Bonaventura ClotetDirector irsiCaixa AIDS Research InstituteVerified email at irsicaixa.es
